Viatris (VTRS)

Executive Summary

Viatris Inc. (NASDAQ: VTRS) is a global pharmaceutical company formed in 2020 from the merger of Mylan and Pfizer’s Upjohn division. The company offers a broad portfolio of branded, generic, complex generic, biosimilar, and OTC products across multiple therapeutic areas, operating in over 165 countries. With a pipeline of 247 drug candidates, Viatris focuses on lifecycle management and leveraging its global scale. Near-term earnings are supported by a diversified product base, but growth hinges on successful launches of new generics and biosimilars, as well as pipeline progression. Key upcoming catalysts include potential FDA approvals for generic versions of high-value branded drugs, progress in respiratory pipeline assets, and expansion of biosimilar offerings. The company’s strong cash flow and cost discipline provide a foundation for shareholder returns, though generic pricing pressures and patent litigation risks remain headwinds.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on generic Entresto (sacubitril/valsartan)45% success
• Q4 2026Phase 3 initiation for TD-4208 (COPD treatment)35% success
• Q1 2027Launch of ustekinumab biosimilar (Stelara copy)60% success